Table 2 Multivariate Cox regression analysis of overall survival in each dataset

Training cohort

 GSE31312 (n = 449)

  Age

1.01–1.04

1.38 × 10⁻⁵

  Extra nodal sites number

1.03–1.41

2.37 × 10⁻²

  Stage

1.12–1.52

6.26 × 10⁻⁵

  ECOG^a

1.21–1.64

7.33 × 10⁻⁶

  Resistance probability of doxorubicin

1.24–5.86

1.23 × 10⁻²

  Resistance probability of vincristine

0.61–2.70

0.51

Validating cohort

 GSE10846 (n = 342)

  Age

1.01–1.04

1.45 × 10⁻⁴

  Extra nodal sites number

0.80–1.22

0.95

  Stage

1.19–1.67

5.40 × 10⁻⁵

  ECOG^a

1.32–1.91

6.43 × 10⁻⁷

  Resistance probability of doxorubicin

1.41–7.45

5.61 × 10⁻³

  Resistance probability of vincristine

0.61–3.23

0.43